The companies will pair Freenome's AI genomics platform with various Qiagen molecular analysis platforms and co-market the technologies to pharmaceutical companies.
CTO Clive Brown provided an overview of the new approach during a presentation at the firm's user meeting last week.
Informaticians at Spain's National Cancer Research Centre develop a methodology for evaluating likely drug efficacy based on specific patient genotypes.
By combining iPSCs, CRISPR gene editing, and transcriptomic approaches, researchers examined the effects of an Alzheimer's disease risk variant on brain cells.
The French firm will assess the ability of its iDtect metagenomic NGS assay to identify pathogenic bacteria and viruses in febrile neutropenia patients.
Two new studies used ancient and modern-day genomes to tease apart Indigenous migrations in the Americas and ancestry patterns by the first Icelandic settlers.
The company is developing tests based on the analysis of the spatial patterns of chromosomes by tagging and imaging their telomeres.
Researchers searched exome sequences of more than 100,000 individuals for associations to more than a dozen quantitative human traits and 10 diseases.
PerkinElmer has added NEXTflex unique dual index barcodes to its NEXTflex family of library prep products. These 192 barcoded adapters provide data security in sequencing applications for use on Illumina platforms. This system is designed to mitigate index hopping and signal spreading, a phenomenon associated with multiplexing. Instruments utilizing a patterned flow cell and exclusion amplification technology experience increased levels of sample misassignment as a result. These adapters address the important issue of sample misidentification, thereby enabling assurance of data integrity, the company said. By allowing researchers to pool multiple libraries in a single flow cell lane, multiplexing with the NEXTflex barcoded adapters also increases processing capacity, while reducing costs.
Five Prime will use an IHC CDx to analyze the use of investigational drug candidates in patients with advanced gastric or gastroesophageal junction cancer.
The NMI Natural and Medical Sciences Institute at the university and its affiliate will use the patents to expand their cell-based research service offerings.
With FALCON-Phase, investigators used PacBio long reads and Hi-C data from Phase Genomics to assemble a haplotype-phased, diploid genome for a hybrid bull.
Castle Biosciences has launched its DecisionDx-CMSeq test, which uses next-generation sequencing to identify somatic mutations in BRAF and NRAS, two genes linked to cutaneous melanoma. The DecisionDx-CMSeq test will provide additional information to compliment the firm's DecisionDx-Melanoma gene expression profile (GEP) test that predicts individual risk of melanoma recurrence in patients. The test can be ordered with the DecisionDx-Melanoma GEP test or as a standalone request.
Precision medicine informatics company GNS Healthcare has named bioinformatician and biomedical engineer Ted Goldstein to its strategic advisory board. Goldstein, scientific program director of computational health at the University of California, San Francisco, is leading development of a machine learning-based comprehensive cancer diagnosis and treatment model for the university. He previously was vice president of developer tools at Apple and an e-commerce hardware developer for Sun Microsystems.
The Center for Genomic Interpretation and NSGC want payors to cover confirmatory testing for patients with positive results from 23andMe's FDA-cleared test.
The firm reported selling more billable tests in Q1 than any previous quarter and said that it is starting to see momentum in new initiatives, such as carrier screening.
The American Cancer Society today lowered the recommended age for screening patients at average risk for the disease to 45 from 50 years old.